Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.

Molecular medicine (Cambridge, Mass.) - 14 Mar 2022

Zhao Binghao, Xia Yu, Yang Fengchun, Wang Yaning, Wang Yuekun, Wang Yadong, Dai Congxin, Wang Yu, Ma Wenbin

Abstract excerpt

BACKGROUND: IDH-mutant astrocytoma and oligodendroglioma have an indolent natural history and are recognized as distinct entities of neoplasms. There is little knowledge on the molecular differences between IDH-mutant astrocytoma and oligodendroglioma grade 2. Therefore, we investigated the multiomics and clinical data regarding these two types of tumors. METHOD: In silico analyses were performed around mRNA,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Deletion

Share to Genomics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35287567
DOI: 10.1186/s10020-022-00454-z
PMCID: PMC8919570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.PMID 35287567Read ↗

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Semantic proximity Read ↗

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes.Semantic proximity Read ↗

DNA Methylation-Based Deconvolution Sheds Light on Glioblastoma Heterogeneity and Cell-Type Composition Associated with Patient SurvivalSemantic proximity Read ↗

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read ↗

DNA Methylation-Based Deconvolution Study of Glioblastoma Heterogeneity and Cell Types Associated with Patient SurvivalSemantic proximity Read ↗

The Cancer Genome Atlas expression profiles of low-grade gliomas.Semantic proximity Read ↗

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seqSemantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.Semantic proximity Read ↗

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Semantic proximity Read ↗

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.